COGT - Cogent Biosciences Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

455.7M

Cash

329.4M

Avg Qtr Burn

-33.86M

Short % of Float

10.34%

Insider Ownership

0.00%

Institutional Own.

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib Details Cancer, Gastrointestinal stromal tumors	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Systemic Mastocytosis Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Systemic Mastocytosis Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.